First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. “We are extremely pleased to begin delivering VYKAT XR ...

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome.

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company with a market capitalization of $3.08 billion, announced today the U.S. commercial availability of VYKAT XR, an FDA-approved ...

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company with a market capitalization of $3.08 billion, announced today the U.S. commercial availability of VYKAT XR ...

Soleno Therapeutics today announced that the US FDA has approved VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and children four years of age and ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...